Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer
In collaboration with the FDA and an independent data monitoring committee, Iovance developed additional safety measures and monitoring.
- In collaboration with the FDA and an independent data monitoring committee, Iovance developed additional safety measures and monitoring.
- Upon reviewing this proposal, the FDA has cleared Iovance to resume patient enrollment in IOV-LUN-202.
- Iovance expects to complete enrollment of approximately 120 patients in the IOV-LUN-202 registrational cohorts in 2025.
- Preliminary data from the IOV-LUN-202 trial support the potential benefit of one-time TIL therapy, including the opportunity for more durable responses than available second line chemotherapies.